{"product_id":"vaccine-contract-manufacturing-market-3rd-edition-2021-2030","title":"Vaccine Contract Manufacturing Market (3rd Edition), 2021-2030","description":"\u003cp\u003eVaccine Contract Manufacturing Market (3rd Edition),    2021-2030    A detailed review of the overall landscape of the vaccine    contract manufacturing market, featuring a list of active CMOs and an analysis    based on a number of relevant parameters, such as year of establishment, size    of employee base, location of headquarters, number of vaccine manufacturing    facilities, type of service(s) offered (cell \/ virus banking, analytical    development \/ testing, formulation, process development, fill \/ finish and    regulatory filings), scale of operation (preclinical, clinical and commercial),    type of expression system used (mammalian, microbial and others) and type of    vaccine manufactured (protein vaccine, viral vaccine, DNA vaccine, cancer    vaccine, and others).            A        detailed review of the contract manufacturing landscape for COVID-19 vaccines,        featuring a list of service providers and an analysis based on type of        service(s) offered (cell \/ virus banking, analytical development \/        testing, formulation, process development, fill \/ finish and regulatory        filings) and geographical location of contract manufacturers (North        America, Europe, and Asia-Pacific and Rest of the World), along with        competitiveness analysis of companies based in different geographies.        A        region-wise company competitiveness analysis, highlighting the most        prominent vaccine contract manufacturers, based on supplier strength (in        terms of experience), and service strength (in terms of service offerings,        expression systems used, and scale of operation).        Elaborate        profiles of the key players based in North America, Europe, and Asia-Pacific        having a diverse range of capabilities for development, manufacturing and        packaging of vaccines. Each profile includes an overview of the company,        its financial performance (if available), information on service        portfolio, vaccine manufacturing facilities, recent developments and an        informed future outlook.         An        analysis of the collaborations that have been established since 2013,        based on various parameters, such as year of agreement, type of agreement,        scale of operation, type of services mentioned in the deal, type of        vaccines manufactured, key therapeutic areas, and location of facility        where the project is to be executed.         A        detailed analysis of the expansions undertaken (since 2013) by various        vaccine contract manufacturing service providers for enhancing their        service portfolios, based on a number of parameters, including year of        expansion, purpose of expansion (capacity expansion, capability expansion,        facility expansion, and new facility), geographical location of facility,        scale of operation, type of service(s) offered, highlighting most active        players and other details (in terms of new area added to existing        facilities, if available).        A        detailed analysis of the various mergers and acquisitions that have taken        place in this domain, highlighting the trend in the number of companies        acquired during the time period between 2013-2021, along with the        geographical distribution of this activity. The analysis also depicts the        relationship between important deal multiples (based on revenues), number        of employees, and overall experience of the acquired company.        A        detailed capacity analysis, taking into consideration the manufacturing        capacities of various stakeholders (small, mid-sized, large \/ very large        CMOs) in the market, based on data gathered via secondary and primary        research. In addition, the study provides the distribution of global        vaccine manufacturing capacity by company size (small, mid-sized, large \/        very large), geography (North America, Europe and Asia-Pacific), and scale        of operation (preclinical \/ clinical and commercial).        An        informed estimate of the annual commercial and clinical demand for        vaccines (in million liters), which was further segmented as across        different types of vaccines, target indications, and geographies.        A        discussion on affiliated trends, key drivers and challenges, under a        comprehensive SWOT framework, which are likely to impact the industry’s        evolution, including a Harvey ball analysis, highlighting the relative        effect of each SWOT parameter on the overall industry.         A        discussion on the potential market drivers, such as the growing vaccines        pipeline, increasing outsourcing of vaccine operations and opportunities        in the Asia-Pacific region, which are likely to present in the coming        years.        One        of the key objectives of the report was to estimate the existing market        size and future growth opportunities. Based on various parameters, such as        growth of the overall vaccine market, cost of goods sold, and direct        manufacturing costs, we have provided informed estimates on the evolution        of the market for the period 2021-2030. The report also features the        likely distribution of the current and forecasted opportunity across [A]        type of expression system used (mammalian, microbial, and others), [B]        scale of operation (preclinical, clinical, and commercial),  [C]        company size (small-, mid-sized and large \/ very large), and [D] key        geographical regions (North America (the US), Europe (Italy, Germany,        France, Spain, and the UK), and Asia-Pacific (China, India, and Japan),        and Rest of the World. In order to account for future uncertainties and to        add robustness to our model, we have provided three market forecast        scenarios, namely conservative, base, and optimistic scenarios,        representing different tracks of the industry’s growth.              The opinions and insights presented in the report were    influenced by discussions held with senior stakeholders in the industry. The    report features detailed transcripts of interviews held with the following    industry stakeholders:         Menzo Havenga, CEO, Batavia Biosciences and Claire Otjes,    Marketing Manager, Batavia Biosciences    Dietmar Katinger, Chief Executive Officer, Polymun    Scientific    David C Cunningham, Director Corporate Development, Goodwin    Biotechnology    Ingrid Kromann, Ex-Director – Vaccine Development (currently,    the Head of CMC at CEPI)    Kevin Daley, Director Pharmaceuticals, Novasep Synthesis    Thilo Kamphausen, Director Business Development,    Richter-Helm BioLogics    Sebastian Schuck, Head of Business Development, Wacker    Biotech     Oliver Schub, Senior Business Development Manager, ProBioGen    All actual figures have been sourced and analyzed from    publicly available information forums and primary research discussions.    Financial figures mentioned in this report are in USD, unless otherwise    specified.         Key Questions Answered         Who are the key players offering vaccine manufacturing    services?    Which manufacturing services are commonly offered by the    vaccine contract manufacturers?    Which partnership models are most commonly adopted by    stakeholders engaged in this industry?    What are the key value drivers of the merger and acquisition    activity within this domain?    What is the current capacity of vaccine contract    manufacturing?    What is the annual commercial and clinical demand for    vaccines?    How is the current and future market opportunity likely to    be distributed across key market segments?    What are the anticipated future trends related to vaccine    contract manufacturing?         PLEASE NOTE: that the publisher limits purchases by    consulting clients to either Consulting Company Team License or Global Site    License for Entire Company. Any other selections will not be fulfilled by this    publisher.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"November, 2023 \/ 381 Pages \/ MCW16256409","offer_id":47650564374834,"sku":null,"price":5759.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/vaccine-contract-manufacturing-market-3rd-edition-2021-2030","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}